Durvalumab with chemotherapy [DUR9]

For neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has a histologically or cytologically determined diagnosis of resectable gastric or gastro‑oesophageal junction (GEJ) adenocarcinoma, and the intent is to treat the patient with radical surgery following systemic neo-adjuvant treatment.
3. The patient has disease which is stage II–III or IVA and is deemed as resectable.
4. The patient has not received any prior chemotherapy or immunotherapy (including anti–CTLA‑4, anti–PD‑1, anti–PD‑L1, or anti–PD‑L2 antibodies) for the treatment of gastric or gastro-oesophageal junction cancer. Note – Patients who have received durvalumab in this indication via the company sponsored early access programme are permitted to move to NHS commissioned supply, only if they meet all other criteria on this form. If applicable to this patient, please select “Yes” for this criterion.
5. In the neo-adjuvant phase, durvalumab will be given alongside FLOT chemotherapy, at a dose of 1,500mg every FOUR weeks, for up to TWO cycles prior to surgery.
6. Treatment with adjuvant durvalumab monotherapy will be given at a dose of 1,500mg every FOUR weeks as below • For up to TWO cycles in combination with FLOT chemotherapy, followed by • Up to TEN cycles as monotherapy.
7. Treatment with adjuvant durvalumab will continue until disease progression or unacceptable toxicity or withdrawal of patient consent or for a maximum total of TWELVE doses post- surgery (this total includes any adjuvant doses of durvalumab given alongside FLOT chemotherapy), whichever occurs first.
8. The patient has a current ECOG performance status of 0 or 1.
9. When a treatment break of more than 12 weeks beyond the expected 4-weekly cycle length is needed, a treatment break approval form will be completed to restart treatment. This must be approved before durvalumab is re-commenced.
10. Durvalumab will be otherwise used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 14 May 2026 - anticipated to move to NHS funding: 01 September 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.402 of the CDF list, downloaded from NHS England’s website on 06 June 2026 at 09:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• DUR9_prior_to_cdf_1.399
• DUR9_prior_to_cdf_1.402